Induction of secretory immunity and memory at mucosal surfaces

Vaccine

Volumn 25, Issue 30 SPEC. ISS., 2007, Pages 5467-5484

  Brandtzaeg, Per ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

BALT; GALT; Gut mucosa; IgG; Immune exclusion; Immunoglobulin A (IgA); MALT; Mucosal immunity; Mucosal vaccines; NALT; Nasal mucosa; Polymeric Ig receptor; Secretory component; Secretory IgA; Secretory IgM; Secretory immunity

Indexed keywords

ADENOVIRUS VACCINE; CHOLERA VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN A ANTIBODY; INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE; NASALFLU; ORAL POLIOMYELITIS VACCINE; ROTAVIRUS VACCINE; TYPHOID VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; B LYMPHOCYTE ACTIVATION; BREAST MILK; CD4+ T LYMPHOCYTE; CHOLERA; CLADISTICS; CROSS REACTION; FACIAL NERVE PARALYSIS; HUMAN; HUMORAL IMMUNITY; IMMUNOSTIMULATION; INFECTION PREVENTION; INFLUENZA; INTESTINE LYMPHATIC TISSUE; INTUSSUSCEPTION; LAMINA PROPRIA; LYMPH FOLLICLE; LYMPHOCYTE HOMING; MEMORY CELL; MUCOSAL IMMUNITY; NONHUMAN; PERINATAL PERIOD; PEYER PATCH; POLIOMYELITIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; TYPHOID FEVER; UNSPECIFIED SIDE EFFECT; VIBRIO CHOLERAE; VIRUS INFECTION; VIRUS LIKE AGENT;

EID: 34447099136     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.12.001     Document Type: Review

References (193)

1. World Health Report 2005. Annex Tables 3 and 4. World Health Organization.
2. Mitragotri S. Immunization without needles. Nat Rev Immunol 5 (2005) 905-916
3. Levine M.M. Can needle-free administration of vaccines become the norm in global immunization?. Nat Med 9 (2003) 99-103
4. Neutra M.R., and Kozlowski P.A. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 6 (2006) 148-158
5. Brandtzaeg P. Role of secretory antibodies in the defence against infections. Int J Med Microbiol 293 (2003) 3-15
6. Brandtzaeg P., and Pabst R. Let's go mucosal: communication on slippery ground. Trends Immunol 25 (2004) 570-577
7. Brandtzaeg P., Farstad I.N., Johansen F.-E., Morton H.C., Norderhaug I.N., and Yamanaka T. The B-cell system of human mucosae and exocrine glands. Immunol Rev 171 (1999) 45-87
8. Brandtzaeg P., and Johansen F.-E. Mucosal B cells: phenotypic characteristics, transcriptional regulation, and homing properties. Immunol Rev 206 (2005) 32-63
9. Brandtzaeg P., Nilssen D.E., Rognum T.O., and Thrane P.S. Ontogeny of the mucosal immune system and IgA deficiency. Gastroenterol Clin N Am 20 (1991) 397-439
10. Anonymous. A warm chain for breastfeeding (Editorial). Lancet 344 (1994) 1239-1241
11. Hanson LÅ, Ashraf R, Carlsson B, Jalil F, Karlberg J, Lindblad BS, et al. Child health and the population increase. In: Hanson LÅ, Köhler L, editors. Peace, health and development. NHV Report 4. Stockholm: GOTAB; 1993. p. 31-8.
12. Jones G., et al. How many child deaths can we prevent this year?. Lancet 362 (2003) 65-71
13. Jong-wook L. Global health improvement and WHO: shaping the future. Lancet 362 (2003) 2083-2088
14. Dickinson E.C., Gorga J.C., Garrett M., Tuncer R., Boyle P., Watkins S.C., et al. Immunoglobulin A supplementation abrogates bacterial translocation and preserves the architecture of the intestinal epithelium. Surgery 124 (1998) 284-290
15. Hylander M.A., Strobino D.M., and Dhanireddy R. Human milk feedings and infection among very low birth weight infants. Pediatrics 102 (1998) E38
16. Pisacane A., Graziano L., Zona G., Granata G., Dolezalova H., Cafiero M., et al. Breast feeding and acute lower respiratory infection. Acta Paediatr 83 (1994) 714-718
17. Wold A.E., and Hanson L.A. Defense factors in human milk. Curr Opin Gastroenterol 10 (1994) 652-658
18. Newman J. How breast milk protects newborns. Sci Am 273 (1995) 58-61
19. Wright A.L., Bauer M., Naylor A., Sutcliffe E., and Clark L. Increasing breastfeeding rates to reduce infant illness at the community level. Pediatrics 101 (1998) 837-844
20. Ogra S.S., Weintraub D., and Ogra P.L. Immunologic aspects of human colostrum and milk. III. Fate and absorption of cellular and soluble components in the gastrointestinal tract of the newborn. J Immunol 119 (1977) 245-248
21. Klemola T., Savilahti E., and Leinikki P. Mumps IgA antibodies are not absorbed from human milk. Acta Paediatr Scand 75 (1986) 230-232
22. Weaver L.T., Wadd N., Taylor C.E., Greenwell J., and Toms G.L. The ontogeny of serum IgA in the newborn. Pediatr Allergy Immunol 2 (1991) 2-75
23. van Elburg R.M., Uil J.J., de Monchy J.G., and Heymans H.S. Intestinal permeability in pediatric gastroenterology. Scand J Gastroenterol 194 Suppl. (1992) 19-24
24. Hooper L.V., Wong M.H., Thelin A., Hansson L., Falk P.G., and Gordon J.I. Molecular analysis of commensal host-microbial relationships in the intestine. Science 291 (2001) 881-884
25. Neish A.S., Gewirtz A.T., Zeng H., Young A.N., Hobert M.E., Karmali V., et al. Prokaryotic regulation of epithelial responses by inhibition of IκB-α ubiquitination. Science 289 (2000) 1560-1563
26. Crabbé P.A., Nash D.R., Bazin H., Eyssen H., and Heremans J.F. Immunohistochemical observations on lymphoid tissues from conventional and germ-free mice. Lab Invest 22 (1970) 448-457
27. Yamanaka T., Helgeland L., Farstad I.N., Midtvedt T., Fukushima H., and Brandtzaeg P. Microbial colonization drives lymphocyte accumulation and differentiation in the follicle-associated epithelium of Peyer's patches. J Immunol 170 (2003) 816-822
28. Brandtzaeg P., Baekkevold E.S., Farstad I.N., Jahnsen F.L., Johansen F.-E., Nilsen E.M., et al. Regional specialization in the mucosal immune system: what happens in the microcompartments?. Immunol Today 20 (1999) 141-151
29. Brandtzaeg P., Farstad I.N., and Haraldsen G. Regional specialization in the mucosal immune system: primed cells do not always home along the same track. Immunol Today 20 (1999) 267-277
30. Hiller A.S., Tschernig T., Kleemann W.J., and Pabst R. Bronchus-associated lymphoid tissue (BALT) and larynx-associated lymphoid tissue (LALT) are found at different frequencies in children, adolescents and adults. Scand J Immunol 47 (1998) 159-162
31. Brandtzaeg P., Halstensen T.S., Kett K., Krajci P., Kvale D., Rognum T.O., et al. Immunobiology and immunopathology of human gut mucosa: humoral immunity and intraepithelial lymphocytes. Gastroenterology 97 (1989) 1562-1584
32. Brandtzaeg P., Morton H.C., and Lamm M.E. Characteristics of mucosal B cells with emphasis on the human secretory immune system. In: Honjo T., Alt F.W., and Neuberger M.S. (Eds). Molecular biology of B cells (2004), Elsevier Science, London 223-246
33. Neutra M.R., Mantis N.J., and Kraehenbuhl J.P. Collaboration of epithelial cells with organized mucosal lymphoid tissues. Nat Immunol 2 (2001) 1004-1009
34. Rescigno M., Urbano M., Valzasina B., Francolini M., Rotta G., Bonasio R., et al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat Immunol 2 (2001) 361-367
35. Milling S.W., Cousins L., and MacPherson G.G. How do DCs interact with intestinal antigens?. Trends Immunol 26 (2005) 349-352
36. Bjerke K., and Brandtzaeg P. Lack of relation between expression of HLA-DR and secretory component (SC) in follicle-associated epithelium of human Peyer's patches. Clin Exp Immunol 71 (1988) 502-507
37. Christ A.D., and Blumberg R.S. The intestinal epithelial cell: immunological aspects. Springer Sem Immunopathol 18 (1997) 449-461
38. Yamanaka T., Straumfors A., Morton H., Fausa O., Brandtzaeg P., and Farstad I. M cell pockets of human Peyer's patches are specialized extensions of germinal centers. Eur J Immunol 31 (2001) 107-117
39. Brandtzaeg P., Baekkevold E.S., and Morton H.C. From B to A the mucosal way. Nat Immunol 2 (2001) 1093-1094
40. Fagarasan S., and Honjo T. Intestinal IgA synthesis: regulation of front-line body defences. Nat Rev Immunol 3 (2003) 63-72
41. Kunkel E.J., and Butcher E.C. Chemokines and the tissue-specific migration of lymphocytes. Immunity 16 (2002) 1-4
42. Lanning D.K., Rhee K.J., and Knight K.L. Intestinal bacteria and development of the B-lymphocyte repertoire. Trends Immunol 26 (2005) 419-425
43. Mazmanian S.K., Liu C.H., Tzianabos A.O., and Kasper D.L. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 122 (2005) 107-118
44. Manser T. Textbook germinal centers?. J Immunol 172 (2004) 3369-3375
45. Macpherson A.J., Lamarre A., McCoy K., Harriman G.R., Odermatt B., Dougan G., et al. IgA production without μ or δ chain expression in developing B cells. Nat Immunol 2 (2001) 625-631
46. Macpherson A.J., Geuking M.B., and McCoy K.D. Immune responses that adapt the intestinal mucosa to commensal intestinal bacteria. Immunology 115 (2005) 153-162
47. Rhee K.J., Sethupathi P., Driks A., Lanning D.K., and Knight K.L. Role of commensal bacteria in development of gut-associated lymphoid tissues and preimmune antibody repertoire. J Immunol 172 (2004) 1118-1124
48. Casola S., Otipoby K.L., Alimzhanov M., Humme S., Uyttersprot N., Kutok J.L., et al. B cell receptor signal strength determines B cell fate. Nat Immunol 5 (2004) 317-327
49. Beisner D.R., Ch'en I.L., Kolla R.V., Hoffmann A., and Hedrick S.M. Cutting edge: innate immunity conferred by B cells is regulated by caspase-8. J Immunol 175 (2005) 3469-3473
50. Bernasconi N.L., Traggiai E., and Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298 (2002) 2199-2202
51. Pasare C., and Medzhitov R. Control of B-cell responses by Toll-like receptors. Nature 438 (2005) 364-368
52. Pulendran B., and Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell 124 (2006) 849-863
53. Ganley-Leal L.M., Liu X., and Wetzler L.M. Toll-like receptor 2-mediated human B cell differentiation. Clin Immunol 120 (2006) 272-284
54. Holmgren J., and Czerkinsky C. Mucosal immunity and vaccines. Nat Med 11 4 Suppl. (2005) S45-S53
55. Ogier A., Franco M.A., Charpilienne A., Cohen J., Pothier P., and Kohli E. Distribution and phenotype of murine rotavirus-specific B cells induced by intranasal immunization with 2/6 virus-like particles. Eur J Immunol 35 (2005) 2122-2130
56. Johansen F.-E., Baekkevold E.S., Carlsen H.S., Farstad I.N., Soler D., and Brandtzaeg P. Regional induction of adhesion molecules and chemokine receptors explains disparate homing of human B cells to systemic and mucosal effector sites: dispersion from tonsils. Blood 106 (2005) 593-600
57. Kilian M., Reinholdt J., Lomholt H., Poulsen K., and Frandsen E.V. Biological significance of IgA1 proteases in bacterial colonization and pathogenesis: critical evaluation of experimental evidence. APMIS 104 (1996) 321-338
58. Weiser J.N., Bae D., Fasching C., Scamurra R.W., Ratner A.J., and Janoff E.N. Antibody-enhanced pneumococcal adherence requires IgA1 protease. Proc Natl Acad Sci USA 100 (2003) 4215-4220
59. + T cells activated in cutaneous or mucosal lymphoid tissues. J Exp Med 195 (2002) 135-141
60. Iwata M., Hirakiyama A., Eshima Y., Kagechika H., Kato C., and Song S.Y. Retinoic acid imprints gut-homing specificity on T cells. Immunity 21 (2004) 527-538
61. Jahnsen F.L., Gran E., Haye R., and Brandtzaeg P. Human nasal mucosa contains antigen-presenting cells of strikingly different functional phenotypes. Am J Respir Cell Mol Biol 30 (2004) 31-37
62. Kroese F.G., Butcher E.C., Stall A.M., Lalor P.A., Adams S., and Herzenberg L.A. Many of the IgA producing plasma cells in murine gut are derived from self-replenishing precursors in the peritoneal cavity. Int Immunol 1 (1989) 75-84
63. Macpherson A.J., Gatto D., Sainsbury E., Harriman G.R., Hengartner H., and Zinkernagel R.M. A primitive T cell-independent mechanism of intestinal mucosal IgA responses to commensal bacteria. Science 288 (2000) 2222-2226
64. Bos N.A., Bun J.C., Popma S.H., Cebra E.R., Deenen G.J., van der Cammen M.J., et al. Monoclonal immunoglobulin A derived from peritoneal B cells is encoded by both germ line and somatically mutated VH genes and is reactive with commensal bacteria. Infect Immun 64 (1996) 616-623
65. Shroff K.E., Meslin K., and Cebra J.J. Commensal enteric bacteria engender a self-limiting humoral mucosal immune response while permanently colonizing the gut. Infect Immun 63 (1995) 3904-3913
66. Umesaki Y., Okada Y., Matsumoto S., Imaoka A., and Setoyama H. Segmented filamentous bacteria are indigenous intestinal bacteria that activate intraepithelial lymphocytes and induce MHC class II molecules and fucosyl asialo GM1 glycolipids on the small intestinal epithelial cells in the ex-germ-free mouse. Microbiol Immunol 39 (1995) 555-562
67. Bos N.A., Jiang H.Q., and Cebra J.J. T cell control of the gut IgA response against commensal bacteria. Gut 48 (2001) 762-764
68. Talham G.L., Jiang H.Q., Bos N.A., and Cebra J.J. Segmented filamentous bacteria are potent stimuli of a physiologically normal state of the murine gut mucosal immune system. Infect Immun 67 (1999) 1992-2000
69. Jiang H.-Q., Bos N.A., and Cebra J.J. Timing, localization, and persistence of colonization by segmented filamentous bacteria in the neonatal mouse gut depend on immune status of mothers and pups. Infect Immun 69 (2001) 3611-3617
70. Stoel M., Jiang H.Q., van Diemen C.C., Bun J.C., Dammers P.M., Thurnheer M.C., et al. Restricted IgA repertoire in both B-1 and B-2 cell-derived gut plasmablasts. J Immunol 174 (2005) 1046-1054
71. H gene analysis suggests that peritoneal B cells do not contribute to the gut immune system in man. Eur J Immunol 32 (2002) 2427-2436
72. Dunn-Walters D.K., Boursier L., and Spencer J. Hypermutation, diversity and dissemination of human intestinal lamina propria plasma cells. Eur J Immunol 27 (1997) 2959-2964
73. Fischer M., and Kuppers R. Human IgA- and IgM-secreting intestinal plasma cells carry heavily mutated VH region genes. Eur J Immunol 28 (1998) 2971-2977
74. Boursier L., Dunn-Walters D.K., and Spencer J. Characteristics of IgVH genes used by human intestinal plasma cells from childhood. Immunology 97 (1999) 558-564
75. Dunn-Walters D.K., Hackett M., Boursier L., Ciclitira P.J., Morgan P., Challacombe S.J., et al. Characteristics of human IgA and IgM genes used by plasma cells in the salivary gland resemble those used in duodenum but not those used in the spleen. J Immunol 164 (2000) 1595-1601
76. Holtmeier W., Hennemann A., and Caspary W.F. IgA and IgM V(H) repertoires in human colon: evidence for clonally expanded B cells that are widely disseminated. Gastroenterology 119 (2000) 1253-1266
77. Dunn-Walters D.K., Isaacson P.G., and Spencer J. Sequence analysis of human IgVH genes indicates that ileal lamina propria plasma cells are derived from Peyer's patches. Eur J Immunol 27 (1997) 463-467
78. Bouvet J.P., and Fischetti V.A. Diversity of antibody-mediated immunity at the mucosal barrier. Infect Immun 67 (1999) 2687-2691
79. Brandtzaeg P. Presence of J chain in human immunocytes containing various immunoglobulin classes. Nature 252 (1974) 418-420
80. Johansen F.-E., Braathen R., and Brandtzaeg P. Role of J chain in secretory immunoglobulin formation. Scand J Immunol 52 (2000) 240-248
81. Johansen F.-E., Braathen R., and Brandtzaeg P. The J chain is essential for polymeric Ig receptor-mediated epithelial transport of IgA. J Immunol 167 (2001) 5185-5192
82. Brandtzaeg P. Mucosal and glandular distribution of immunoglobulin components: differential localization of free and bound SC in secretory epithelial cells. J Immunol 112 (1974) 1553-1559
83. Brandtzaeg P., and Prydz H. Direct evidence for an integrated function of J chain and secretory component in epithelial transport of immunoglobulins. Nature 311 (1984) 71-73
84. Norderhaug I.N., Johansen F.-E., Schjerven H., and Brandtzaeg P. Regulation of the formation and external transport of secretory immunoglobulins. Crit Rev Immunol 19 (1999) 481-508
85. Phalipon A., and Corthésy B. Novel functions of the polymeric Ig receptor: well beyond transport of immunoglobulins. Trends Immunol 24 (2003) 55-58
86. Berdoz J., Blanc C.T., Reinhardt M., Kraehenbuhl J.P., and Corthesy B. In vitro comparison of the antigen-binding and stability properties of the various molecular forms of IgA antibodies assembled and produced in CHO cells. Proc Natl Acad Sci USA 96 (1999) 3029-3034
87. Conley M.E., and Delacroix D.L. Intravascular and mucosal immunoglobulin A: two separate but related systems of immune defense?. Ann Intern Med 106 (1987) 892-899
88. Brandtzaeg P., Halstensen T.S., Huitfeldt H.S., Krajci K., Kvale D., Scott H., et al. Epithelial expression of HLA, secretory component (poly-Ig receptor), and adhesion molecules in the human alimentary tract. Ann N Y Acad Sci 664 (1992) 157-179
89. Schjerven H., Brandtzaeg P., and Johansen F.-E. Mechanism of IL-4-mediated up-regulation of the polymeric Ig receptor: role of STAT6 in cell type-specific delayed transcriptional response. J Immunol 165 (2000) 3898-3906
90. Schjerven H., Brandtzaeg P., and Johansen F.-E. A novel NF-κB/Rel site in intron 1 cooperates with proximal promoter elements to mediate TNF-α-induced transcription of the human polymeric Ig receptor. J Immunol 167 (2001) 6412-6420
91. Johansen F.-E., and Brandtzaeg P. Transcriptional regulation of the mucosal IgA system. Trends Immunol 25 (2004) 150-157
92. Ha C.L., and Woodward B. Depression in the quantity of intestinal secretory IgA and in the expression of the polymeric immunoglobulin receptor in caloric deficiency of the weanling mouse. Lab Invest 78 (1998) 1255-1266
93. Sarkar J., Gangopadhyay N.N., Moldoveanu Z., Mestecky J., and Stephensen C.B. Vitamin A is required for regulation of polymeric immunoglobulin receptor (pIgR) expression by interleukin-4 and interferon-gamma in a human intestinal epithelial cell line. J Nutr 128 (1998) 1063-1069
94. Muller C.A., Autenrieth I.B., and Peschel A. Innate defenses of the intestinal epithelial barrier. Cell Mol Life Sci 62 (2005) 1297-1307
95. Haneberg B. Immunoglobulins in feces from infants fed human or bovine milk. Scand J Immunol 3 (1974) 191-197
96. Ma J.K., Hikmat B.Y., Wycoff K., Vine N.D., Chargelegue D., Yu L., et al. Characterization of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in humans. Nat Med 4 (1998) 601-606
97. Quan C.P., Berneman A., Pires R., Avrameas S., and Bouvet J.P. Natural polyreactive secretory immunoglobulin A autoantibodies as a possible barrier to infection in humans. Infect Immun 65 (1997) 3997-4004
98. Bouvet J.P., and Dighiero G. From natural polyreactive autoantibodies to a la carte monoreactive antibodies to infectious agents: is it a small world after all?. Infect Immun 66 (1998) 1-4
99. Brandtzaeg P., Fjellanger I., and Gjeruldsen S.T. Adsorption of immunoglobulin A onto oral bacteria in vivo. J Bacteriol 96 (1968) 242-249
100. van der Waaij L.A., Limburg P.C., Mesander G., and van der Waaij D. In vivo IgA coating of anaerobic bacteria in human faeces. Gut 38 (1996) 348-354
101. Kronvall G., Simmons A., Myhre E.B., and Jonsson S. Specific absorption of human serum albumin, immunoglobulin A, and immunoglobulin G with selected strains of group A and G streptococci. Infect Immun 25 (1979) 1-10
102. Roy M.J., and Varvayanis M. Development of dome epithelium in gut-associated lymphoid tissues: association of IgA with M cells. Cell Tissue Res 248 (1987) 645-651
103. Mantis N.J., Cheung M.C., Chintalacharuvu K.R., Rey J., Corthesy B., and Neutra M.R. Selective adherence of IgA to murine Peyer's patch M cells: evidence for a novel IgA receptor. J Immunol 169 (2002) 1844-1851
104. Rey J., Garin N., Spertini F., and Corthesy B. Targeting of secretory IgA to Peyer's patch dendritic and T cells after transport by intestinal M cells. J Immunol 172 (2004) 3026-3033
105. Favre L., Spertini F., and Corthesy B. Secretory IgA possesses intrinsic modulatory properties stimulating mucosal and systemic immune responses. J Immunol 175 (2005) 2793-2800
106. Brandtzaeg P. The secretory immunoglobulin system: regulation and biological significance. Focusing on mammary glands. In: Davis MK, Isaacs CE, Hanson LÅ, Wright AL, editors. Integrating population outcomes, biological mechanisms and research methods in the study of human milk and lactation. New York: Kluwer Academic/Plenum Publishers. Adv Exp Med 2002;503:1-16.
107. Macpherson A.J., and Uhr T. Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. Science 303 (2004) 1662-1665
108. Goldblum R.M., Hanson LÅ, and Brandtzaeg P. The mucosal defense system. In: Stiehm E.R. (Ed). Immunologic disorders in infants, children. 4th ed. (1996), W.B. Saunders Co., Philadelphia 159-199
109. Renegar K.B., Jackson G.D., and Mestecky J. In vitro comparison of the biologic activities of monoclonal monomeric IgA, polymeric IgA, and secretory IgA. J Immunol 160 (1998) 1219-1223
110. Berdoz J., and Corthesy B. Human polymeric IgA is superior to IgG and single-chain Fv of the same monoclonal specificity to inhibit urease activity associated with Helicobacter pylori. Mol Immunol 41 (2004) 1013-1022
111. Hocini H., Bélec L., Iscaki S., Garin B., Pillot J., Becquart P., et al. High-level ability of secretory IgA to block HIV type 1 transcytosis: contrasting secretory IgA and IgG responses to glycoprotein 160. AIDS Res Hum Retrovirus 13 (1997) 1179-1185
112. Mazzoli S., Trabattoni D., Lo Caputo S., Piconi S., Blé C., Meacci F., et al. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat Med 3 (1997) 1250-1257
113. Bollinger R.R., Everett M.L., Palestrant D., Love S.D., Lin S.S., and Parker W. Human secretory immunoglobulin A may contribute to biofilm formation in the gut. Immunology 109 (2003) 580-587
114. Porter P., and Linggood M.A. Novel mucosal anti-microbial functions interfering with the plasmid-mediated virulence determinants of adherence and drug resistance. Ann N Y Acad Sci 409 (1983) 564-578
115. Rogers H.J., and Synge C. Bacteriostatic effect of human milk on Escherichia coli: the role of IgA. Immunology 34 (1978) 19-28
116. Tenovuo J., Moldoveanu Z., Mestecky J., Pruitt K.M., and Rahemtulla B.M. Interaction of specific and innate factors of immunity: IgA enhances the antimicrobial effect of the lactoperoxidase system against Streptococcus mutans. J Immunol 128 (1982) 726-731
117. Burns J.W., Siadat-Pajouh M., Krishnaney A.A., and Greenberg H.B. Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity. Science 272 (1996) 104-107
118. Bomsel M., Heyman M., Hocini H., Lagaye S., Belec L., Dupont C., et al. Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dIgA or IgM. Immunity 9 (1998) 277-287
119. Fujioka H., Emancipator S.N., Aikawa M., Huang D.S., Blatnik F., Karban T., et al. Immunocytochemical colocalization of specific immunoglobulin A with sendai virus protein in infected polarized epithelium. J Exp Med 188 (1998) 1223-1229
120. Mazanec M.B., Coudret C.L., and Fletcher D.R. Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies. J Virol 69 (1995) 1339-1343
121. Mazanec M.B., Nedrud J.G., Kaetzel C.S., and Lamm M.E. A three-tiered view of the role of IgA in mucosal defense. Immunol Today 14 (1993) 430-435
122. Robinson J.K., Blanchard T.G., Levine A.D., Emancipator S.N., and Lamm M.E. A mucosal IgA-mediated excretory immune system in vivo. J Immunol 166 (2001) 3688-3692
123. Fernandez M.I., Pedron T., Tournebize R., Olivo-Marin J.C., Sansonetti P.J., and Phalipon A. Anti-inflammatory role for intracellular dimeric immunoglobulin a by neutralization of lipopolysaccharide in epithelial cells. Immunity 18 (2003) 739-749
124. Mostov K.E., and Blobel G. A transmembrane precursor of secretory component. The receptor for transcellular transport of polymeric immunoglobulins. J Biol Chem 257 (1982) 11816-11821
125. Kaetzel C.S. The polymeric immunoglobulin receptor: bridging innate and adaptive immune responses at mucosal surfaces. Immunol Rev 206 (2005) 83-99
126. Giugliano L.G., Ribeiro S.T.G., Vainstein M.H., and Ulhoa C.J. Free secretory component and lactoferrin of human milk inhibit the adhesion of enterotoxigenic Esherichia coli. J Med Microbiol 42 (1995) 3-9
127. Dallas S.D., and Rolfe R.D. Binding of Clostridium difficile toxin A to human milk secretory component. J Med Microbiol 47 (1998) 879-888
128. Hammerschmidt S., Talay S.R., Brandtzaeg P., and Chhatwal G.S. SpsA, a novel pneumococcal surface protein with specific binding to secretory immunoglobulin A and secretory component. Mol Microbiol 25 (1997) 1113-1124
129. Hamre R., Farstad I.N., Brandtzaeg P., and Morton H.C. Expression and modulation of the human immunoglobulin A Fc receptor (CD89) and the FcR γ chain on myeloid cells in blood and tissue. Scand J Immunol 57 (2003) 506-516
130. Lamkhioued B., Gounni A.S., Gruart V., Pierce A., Capron A., and Capron M. Human eosinophils express a receptor for secretory component. Role in secretory IgA-dependent activation. Eur J Immunol 25 (1995) 117-125
131. Marshall L.J., Perks B., Ferkol T., and Shute J.K. IL-8 released constitutively by primary bronchial epithelial cells in culture forms an inactive complex with secretory component. J Immunol 167 (2001) 2816-2823
132. Brandtzaeg P., and Nilssen D.E. Mucosal aspects of primary B-cell deficiency and gastrointestinal infections. Curr Opin Gastroenterol 11 (1995) 532-540
133. Persson C.G., Erjefält J.S., Greiff L., Erjefält I., Korsgren M., Linden M., et al. Contribution of plasma-derived molecules to mucosal immune defence, disease and repair in the airways. Scand J Immunol 47 (1998) 302-313
134. Yoshida M., Claypool S.M., Wagner J.S., Mizoguchi E., Mizoguchi A., Roopenian D.C., et al. Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells. Immunity 20 (2004) 769-783
135. Brandtzaeg P., and Tolo K. Mucosal penetrability enhanced by serum-derived antibodies. Nature 266 (1977) 262-263
136. Berstad A.E., and Brandtzaeg P. Expression of cell-membrane complement regulatory glycoproteins along the normal and diseased human gastrointestinal tract. Gut 42 (1998) 522-529
137. Sun K., Johansen F.-E., Eckmann L., and Metzger D.W. An important role for polymeric Ig receptor-mediated transport of IgA in protection against Streptococcus pneumoniae nasopharyngeal carriage. J Immunol 173 (2004) 4576-4581
138. Uren T.K., Wijburg O.L.C., Simmons C., Johansen F.-E., Brandtzaeg P., and Strugnell R.A. Vaccine-induced protection against gastrointestinal bacterial infections in the absence of secretory antibodies. Eur J Immunol 35 (2005) 180-188
139. Bižanov G., Janakova L., Knapstad S.E., Karlstad T., Bakke H., Haugen I.L., et al. Immunoglobulin-A antibodies in upper airway secretions may inhibit intranasal influenza virus replication in mice but not protect against clinical illness. Scand J Immunol 61 (2005) 503-510
140. Renegar K.B., Small P.A., Boykins L.G., and Wright P.F. Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J Immunol 173 (2004) 1978-1986
141. Daniele R.P. Immunoglobulin secretion in the airways. Annu Rev Physiol 52 (1990) 177-195
142. Velazquez F.R., Matson D.O., Calva J.J., Guerrero L., Morrow A.L., Carter-Campbell S., et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 335 (1996) 1022-1028
143. O'Neal C.M., Clements J.D., Estes M.K., and Conner M.E. Rotavirus 2/6 viruslike particles administered intranasally with cholera toxin, Escherichia coli heat-labile toxin (LT), and LT-R192G induce protection from rotavirus challenge. J Virol 72 (1998) 3390-3393
144. Mbawuike I.N., Pacheco S., Acuna C.L., Switzer K.C., Zhang Y., and Harriman G.R. Mucosal immunity to influenza without IgA: an IgA knockout mouse model. J Immunol 162 (1999) 2530-2537
145. Fazekas de St. Groth S. Studies in experimental immunology of influenza. IX. The mode of action of pathotopic adjuvants. Aust J Exp Biol Med Sci 29 (1951) 339-352
146. -/- mice abrogates the development of allergic lung inflammation. J Immunol 175 (2005) 1276-1285
147. Renegar K.B., Johnson C.D., Dewitt R.C., King B.K., Li J., Fukatsu K., et al. Impairment of mucosal immunity by total parenteral nutrition: requirement for IgA in murine nasotracheal anti-influenza immunity. J Immunol 166 (2001) 819-825
148. Johansen F.-E., Pekna M., Norderhaug I.N., Haneberg B., Hietala M.A., Krajci P., et al. Absence of epithelial immunoglobulin A transport, with increased mucosal leakiness, in polymeric immunoglobulin receptor/secretory component-deficient mice. J Exp Med 190 (1999) 915-921
149. Asahi Y., Yoshikawa T., Watanabe I., Iwasaki T., Hasegawa H., Sato Y., et al. Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines. J Immunol 168 (2002) 2930-2938
150. Waldman R.H., Wigley F.M., and Small Jr. P.A. Specificity of respiratory secretion antibody against influenza virus. J Immunol 105 (1970) 1477-1483
151. Shvartsman Y.S., Agranovskaya E.N., and Zykov M.P. Formation of secretory and circulating antibodies after immunization with live and inactivated influenza virus vaccines. J Infect Dis 135 (1977) 697-705
152. Clements M.L., and Murphy B.R. Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine. J Clin Microbiol 23 (1986) 66-72
153. Lim P.L., and Rowley D. The effect of antibody on the intestinal absorption of macromolecules and on intestinal permeability in adult mice. Int Arch Allergy Appl Immunol 68 (1982) 41-46
154. Lycke N., Erlandsson L., Ekman L., Schon K., and Leanderson T. Lack of J chain inhibits the transport of gut IgA and abrogates the development of intestinal antitoxic protection. J Immunol 163 (1999) 913-919
155. Sanchez J., and Holmgren J. Virulence factors, pathogenesis and vaccine protection in cholera and ETEC diarrhea. Curr Opin Immunol 17 (2005) 388-398
156. Wijburg O.L.C., Uren T.K., Simpfendorfer K., Johansen F.E., Brandtzaeg P., and Strugnell R.A. Innate secretory antibodies protect against natural Salmonella typhimurium infection. J Exp Med 203 (2006) 21-26
157. Ali M., Emch M., von Seidlein L., Yunus M., Sack D.A., Rao M., et al. Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet 366 (2005) 44-49
158. Eriksson K., and Holmgren J. Recent advances in mucosal vaccines and adjuvants. Curr Opin Immunol 14 (2002) 666
159. Kabir S. Cholera vaccines: the current status and problems. Rev Med Microbiol 16 (2005) 101-116
160. Santosuosso M., McCormick S., and Xing Z. Adenoviral vectors for mucosal vaccination against infectious diseases. Viral Immunol 18 (2005) 283-291
161. Glass R.I., Bresee J.S., Parashar U.D., Jiang B., and Gentsch J. The future of rotavirus vaccines: a major setback leads to new opportunities. Lancet 363 (2004) 1547-1550
162. Ruiz-Palacios G.M., et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 354 (2006) 11-22
163. Vesikari T., et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 354 (2006) 23-33
164. van Ginkel F.W., Jackson R.J., Yuki Y., and McGhee J.R. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol 165 (2000) 4778-4782
165. Glück R., Mischler R., Durrer P., Furer E., Lang A.B., Herzog C., et al. Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant. J Infect Dis 181 (2000) 1129-1132
166. Mutsch M., Zhou W., Rhodes P., Bopp M., Chen R.T., Linder T., et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 350 (2004) 896-903
167. Lu X., Clements J.D., and Katz J.M. Mutant Escherichia coli heat-labile enterotoxin [LT(R192G)] enhances protective humoral and cellular immune responses to orally administered inactivated influenza vaccine. Vaccine 20 (2002) 1019-1029
168. Hinkula J., Devito C., Zuber B., Benthin R., Ferreira D., Wahren B., et al. A novel DNA adjuvant, N3, enhances mucosal and systemic immune responses induced by HIV-1 DNA and peptide immunizations. Vaccine 24 (2006) 4494-4497
169. Mason H.S., Warzecha H., Mor T., and Arntzen C.J. Edible plant vaccines: applications for prophylactic and therapeutic molecular medicine. Trends Mol Med 8 (2002) 324-329
170. Yusibov V., Rabindran S., Commandeur U., Twyman R.M., and Fischer R. The potential of plant virus vectors for vaccine production. Drugs R D 7 (2006) 203-217
171. Schillberg S., Twyman R.M., and Fischer R. Opportunities for recombinant antigen and antibody expression in transgenic plants-technology assessment. Vaccine 23 (2005) 1764-1769
172. Belshe R.B., Gruber W.C., Mendelman P.M., Cho I., Reisinger K., Block S.L., et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr 136 (2000) 168-175
173. Devito C., Zuber B., Schröder U., Benthin R., Okuda K., Broliden K., et al. Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity. J Immunol 173 (2004) 7078-7089
174. Brokstad K.A., Cox R.J., Eriksson J.C., Olofsson J., Jonsson R., and Davidsson A. High prevalence of influenza specific antibody secreting cells in nasal mucosa. Scand J Immunol 54 (2001) 243-247
175. Brokstad K.A., Eriksson J.C., Cox R.J., Tynning T., Olofsson J., Jonsson R., et al. Parenteral vaccination against influenza does not induce a local antigen-specific immune response in the nasal mucosa. J Infect Dis 185 (2002) 878-884
176. Brokstad K.A., Cox R.J., Olofsson J., Jonsson R., and Haaheim L.R. Parenteral influenza vaccination induces a rapid systemic and local immune response. J Infect Dis 171 (1995) 198-203
177. El-Madhun A.S., Cox R.J., Søreide A., Olofsson J., and Haaheim L.R. Systemic and mucosal immune responses in young children and adults after parenteral influenza vaccination. J Infect Dis 178 (1998) 933-939
178. Brandtzaeg P. Immunological functions of adenoids. In: van Cauwenberge P., Wang D.-Y., Ingels K., and Bachert C. (Eds). The nose (1998), Kugler Publications, The Hague 233-246
179. McCaughan G.W., Adams E., and Basten A. Human antigen-specific IgA responses in blood and secondary lymphoid tissue: an analysis of help and suppression. J Immunol 132 (1984) 1190-1196
180. Glezen W.P. Influenza vaccination for healthy children. Curr Opin Infect Dis 15 (2002) 283-287
181. Keitel W.A., Cate T.R., Nino D., Huggins L.L., Six H.R., Quarles J.M., et al. Immunization against influenza: comparison of various topical and parenteral regimens containing inactivated and/or live attenuated vaccines in healthy adults. J Infect Dis 183 (2001) 329-332
182. de Bernardi di Valserra M., Zanasi A., Ragusa S., Gluck R., and Herzog C. An open-label comparison of the immunogenicity and tolerability of intranasal and intramuscular formulations of virosomal influenza vaccine in healthy adults. Clin Ther 24 (2002) 100-111
183. Berstad A.K., Andersen S.R., Dalseg R., Dromtorp S., Holst J., Namork E., et al. Inactivated meningococci and pertussis bacteria are immunogenic and act as mucosal adjuvants for a nasal inactivated influenza virus vaccine. Vaccine 18 (2000) 1910-1919
184. Plante M., Jones T., Allard F., Torossian K., Gauthier J., St-Felix N., et al. Nasal immunization with subunit proteosome influenza vaccines induces serum HAI, mucosal IgA and protection against influenza challenge. Vaccine 20 (2001) 218-225
185. Treanor J., Nolan C., O'Brien D., Burt D., Lowell G., Linden J., et al. Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects. Vaccine 24 (2006) 254-262
186. Greenbaum E., Furst A., Kiderman A., Stewart B., Levy R., Schlesinger M., et al. Mucosal [SIgA] and serum [IgG] immunologic responses in the community after a single intra-nasal immunization with a new inactivated trivalent influenza vaccine. Vaccine 20 (2002) 1232-1239
187. Bakke H., Samdal H.H., Holst J., Oftung F., Haugen I.L., Kristoffersen A.C., et al. Oral spray immunization may be an alternative to intranasal vaccine delivery to induce systemic antibodies but not nasal mucosal or cellular immunity. Scand J Immunol 63 (2006) 223-231
188. Bakke H., and Haneberg B. The development of mucosal vaccines. Tidsskr Nor Laegeforen 126 (2006) 2818-2821. http://www.tidsskriftet.no/ [in Norwegian; see http://www.tidsskriftet.no/]
189. Herremans T.M.P.T., Reimerink J.H.J., Buisman A.M., Kimman T.G., and Koopmans M.P. Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus. J Immunol 162 (1999) 5011-5018
190. Kunisawa J., Fukuyama S., and Kiyono H. Mucosa-associated lymphoid tissues in the aerodigestive tract: their shared and divergent traits and their importance to the orchestration of the mucosal immune system. Curr Mol Med 5 (2005) 557-572
191. Henriksson G., Helgeland L., Midtvedt T., Stierna P., and Brandtzaeg P. Immune response to Mycoplasma pulmonis in nasal mucosa is modulated by the normal microbiota. Am J Respir Cell Mol Biol 31 (2004) 657-662
192. Shikina T., Hiroi T., Iwatani K., Jang M.H., Fukuyama S., Tamura M., et al. IgA class switch occurs in the organized nasopharynx- and gut-associated lymphoid tissue, but not in the diffuse lamina propria of airways and gut. J Immunol 172 (2004) 6259-6264
193. Vajdy M., and Singh M. Intranasal delivery of vaccines against HIV. Expert Opin Drug Deliv 3 (2006) 247-259